keyword
MENU ▼
Read by QxMD icon Read
search

heberprot

keyword
https://www.readbyqxmd.com/read/27130382/intralesional-application-of-epidermal-growth-factor-in-limb-threatening-ischemic-diabetic-foot-ulcers
#1
Şamil Aktaş, Selçuk Baktıroğlu, Levent Demir, Önder Kılıçoğlu, Murat Topalan, Erdem Güven, Bengüsu Mirasoğlu, Fatih Yanar
OBJECTIVE: The intralesional injection of recombinant human epidermal growth factor (EGF-IL), a new therapy, has been claimed to prevent major amputations in advanced diabetic foot lesions. In this study, the efficacy of EGF-IL on advanced diabetic foot ulcers (DFU) was reviewed. METHODS: Intralesional 75 µg EGF application (Heberprot-P® 75, Heber Biotec, Havana, Cuba) to 12 diabetic foot lesions in 11 patients (8 males, 3 females; mean age: 62.2±10.6 years) was evaluated...
2016: Acta Orthopaedica et Traumatologica Turcica
https://www.readbyqxmd.com/read/27070878/-analysis-of-the-clinical-application-of-epidermal-growth-factor-heberprot-p-and-bioplastic-material-collost-in-treatment-of-skin-and-soft-tissues-defects-in-patients-with-diabetic-foot-syndrome
#2
M D Dibirov, R U Gadzhimuradov, K A Koreiba
RELEVANCE: Currently, there is increasing the number of diabetic foot patients with tissues defects. The local treatment of this pathology against the backdrop of diabetic angiopathy and polyneuropathy is a topical issue. AIM: Treatment of wound defects in patients with neuroischemic form of diabetic foot syndrome; study of the effectiveness of collagen implants and gene-therapy technologies in wound closure. MATERIAL AND METHODS: The comparative study was conducted for analyzing clinical effects of "Heberprot-P" and bioplastic material "Collost" on wound healing process in patients with verified diagnosis "diabetic foot syndrome" on the base of City Clinical Hospital №81(Moscow) and "Diabetic Foot" center (Kazan)...
2016: Khirurgiia
https://www.readbyqxmd.com/read/26543993/diabetic-foot-and-heberprot-p
#3
J V Pai-Dhungat, Falguni Parikh
No abstract text is available yet for this article.
March 2015: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/25856928/diabetic-foot-and-heberprot-p
#4
J V Pai-Dhungat, Falguni Parikh
No abstract text is available yet for this article.
June 2014: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/25856197/efficacy-of-intralesional-recombinant-human-epidermal-growth-factor-in-chronic-diabetic-foot-ulcers
#5
Mert Dumantepe, Osman Fazliogullari, Mustafa Seren, Ibrahim Uyar, Fahrettin Basar
OBJECTIVE: The aim of this study was to explore the clinical effects of intralesional administration of an epidermal growth factor (EGF) up to complete wound closure. METHODS: Seventeen diabetic patients with full-thickness lower extremity ulcers of more than 4 weeks of evolution were enrolled in the study. Mean ulcer size was 15.5 +/- 7.5 cm(2). Intralesional injections of 75 µg of Heberprot-P three times per week for 5-8 weeks were given up to complete wound healing...
April 2015: Growth Factors
https://www.readbyqxmd.com/read/23396236/heberprot-p-a-novel-product-for-treating-advanced-diabetic-foot-ulcer
#6
Jorge Berlanga, José I Fernández, Ernesto López, Pedro A López, Amaurys del Río, Carmen Valenzuela, Julio Baldomero, Verena Muzio, Manuel Raíces, Ricardo Silva, Boris E Acevedo, Luis Herrera
Diabetic foot ulcer is a principal diabetic complication. It has been shown that diabetic patients have decreased growth factor concentrations in their tissues, particularly epidermal growth factor. Growth factor shortage impairs wound healing, which leads to chronic nonhealing wounds and sometimes eventual amputation. Ischemic diabetic foot ulcer is the most difficult to treat and confers the highest amputation risk. Injecting epidermal growth factor deep into the wound bottom and contours encourages a more effective pharmacodynamic response in terms of granulation tissue growth and wound closure...
January 2013: MEDICC Review
https://www.readbyqxmd.com/read/19291119/intralesional-administration-of-epidermal-growth-factor-based-formulation-heberprot-p-in-chronic-diabetic-foot-ulcer-treatment-up-to-complete-wound-closure
#7
José I Fernández-Montequín, Blas Y Betancourt, Gisselle Leyva-Gonzalez, Ernesto L Mola, Katia Galán-Naranjo, Mayte Ramírez-Navas, Sergio Bermúdez-Rojas, Felix Rosales, Elizeth García-Iglesias, Jorge Berlanga-Acosta, Ricardo Silva-Rodriguez, Marianela Garcia-Siverio, Luis H Martinez
Previous studies have shown that an epidermal growth factor-based formulation (Heberprot-P) can enhance granulation of high-grade diabetic foot ulcers (DFU). The aim of this study was to explore the clinical effects of this administration up to complete wound closure. A pilot study in 20 diabetic patients with full-thickness lower extremity ulcers of more than 4 weeks of evolution was performed. Mean ulcer size was 16.3 +/- 21.3 cm(2). Intralesional injections of 75 microg of Heberprot-P three times per week were given up to complete wound healing...
February 2009: International Wound Journal
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"